Compare CLMB & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLMB | KMDA |
|---|---|---|
| Founded | 1982 | 1990 |
| Country | United States | Israel |
| Employees | N/A | 374 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.8M | 501.8M |
| IPO Year | 1996 | 2013 |
| Metric | CLMB | KMDA |
|---|---|---|
| Price | $80.32 | $8.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $120.00 | $14.00 |
| AVG Volume (30 Days) | 65.8K | ★ 67.3K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | 0.63% | ★ 5.19% |
| EPS Growth | ★ 14.29 | N/A |
| EPS | ★ 4.64 | N/A |
| Revenue | ★ $652,517,000.00 | N/A |
| Revenue This Year | $2.60 | $14.04 |
| Revenue Next Year | $1.93 | $7.99 |
| P/E Ratio | ★ $17.36 | $24.59 |
| Revenue Growth | ★ 40.14 | N/A |
| 52 Week Low | $79.26 | $5.54 |
| 52 Week High | $145.00 | $9.35 |
| Indicator | CLMB | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 24.97 | 52.87 |
| Support Level | $80.08 | $6.69 |
| Resistance Level | $112.37 | $8.88 |
| Average True Range (ATR) | 5.40 | 0.28 |
| MACD | -0.93 | -0.07 |
| Stochastic Oscillator | 7.98 | 47.42 |
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.